Metal ion polyphenol drug-loaded coating material as well as preparation method and application thereof

By combining strontium ions, copper ions and drugs on polyphenol polymers, forming a metal phenolamine network and combining polypeptides or proteins, the problem of insufficient performance of existing coatings is solved, and endothelial cell proliferation promotion, smooth muscle cell inhibition and biological development are achieved. The stability of macromolecules sustained release has excellent NO catalytic release and sustained release properties.

CN118976163APending Publication Date: 2024-11-19DONGGUAN PEOPLES HOSPITAL
View PDF 0 Cites 2 Cited by

Patent Information

Application Number
CN202411101917.0
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-08-12
Publication Date
2024-11-19

AI Technical Summary

Technical Problem

The existing metal-ion polyphenol-loaded coatings have insufficient performance in promoting endothelial cell adhesion and proliferation and inhibiting smooth muscle cell adhesion and proliferation. At the same time, the sustained release performance of biological functional macromolecules is unstable.

Method used

Polyphenol polymers are used to combine strontium ions, copper ions and drugs to form a metal phenolamine network through coordination and cation interaction, and to achieve in-situ drug loading with polypeptides or proteins to prepare a multifunctional metal ion polyphenol drug-loading coating. layer.

Benefits of technology

Improve the adhesion and proliferation ability of the coating, inhibit the adhesion and proliferation of smooth muscle cells, and realize the stable sustained release performance of biological functional macromolecules. It has long-term and controllable NO catalytic release and slow release of polypeptides or proteins. Release performance.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN118976163A_ABST
    Figure CN118976163A_ABST
Patent Text Reader

Abstract

The invention discloses a metal ion polyphenol drug-loaded coating material as well as a preparation method and application thereof, and relates to the technical field of biological materials. The multifunctional drug-loaded coating is prepared by combining first metal ions, second metal ions and drugs on a polyphenol polymer. A metal phenol-amine network formed by polyphenol and Sr < 2 + >, Cu < 2 + > / Zn < 2 + > not only can enhance the physiological action of plant polyphenol and metal ions, but also can play a synergistic effect to generate stronger biological activities such as oxidation resistance, inflammation resistance and bacteria resistance. In-situ drug loading is achieved based on the physical adsorption effect between polyphenol and polypeptide or protein, and the lasting and stable slow release performance of polypeptide or protein is achieved. The metal ion polyphenol drug-loaded coating material provided by the invention can improve the ability of promoting endothelial cell adhesion and proliferation and the ability of inhibiting smooth muscle cell adhesion and proliferation of a coating at the same time, can realize stable slow release performance of biological functional macromolecules, and has a very good application prospect.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The invention relates to the technical field of biomaterials, and in particular to a metal ion polyphenol drug-carrying coating material, a preparation method and application thereof. Background Art

[0002] Plant polyphenols are a class of natural compounds that are mainly derived from roots, stems, leaves and fruits in plant tissues. These compounds have a polyphenol structure and are well-known for their powerful antioxidant and anti-inflammatory effects. They have physiological functions such as scavenging free radicals, reducing oxidative damage, anti-inflammatory, and anti-platelet aggregation. Because they contain multiple phenolic functional groups, they can interact with metal ions through coordination, cation II, etc. to form stable complexes.

[0003] As biological functional macromolecules, peptides and proteins play an important role in the body. However, there are still certain limitations in achieving peptide and protein drug loading. One of the main challenges is the complex structure and easy degradation of these biomacromolecules, which limits their stability and bioavailability in the body. In addition, the high molecular weight and polar properties of peptide and protein drugs also increase the difficulty of designing drug delivery systems. It is of great significance to overcome these challenges and explore the loading strategies of peptide and protein drugs.

[0004] At present, plant polyphenols combined with metal ions can form multifunctional coatings. At the same time, the coatings can further introduce biofunctional macromolecules such as peptides or proteins. However, the current preparation process has the following problems: (1) The comprehensive performance of the coating needs to be further improved, such as improving the coating's ability to promote endothelial cell adhesion and proliferation, improving the coating's ability to inhibit smooth muscle cell adhesion and proliferation, etc.; (2) The sustained-release performance of the loaded biofunctional macromolecules needs to be further improved, and there is an urgent need to develop coatings with stable sustained-release performance.

[0005] In view of this, the present invention is proposed. Summary of the invention

[0006] The purpose of the present invention is to provide a metal ion polyphenol drug-loaded coating material, a preparation method and application thereof, aiming to simultaneously improve the coating's ability to promote endothelial cell adhesion and proliferation, inhibit smooth muscle cell adhesion and proliferation, and achieve stable sustained release performance of biological functional macromolecules.

[0007] The present invention is achieved in that:

[0008] In a first aspect, the present invention provides a metal ion polyphenol drug-carrying coating material, comprising a substrate and a metal ion polyphenol drug-carrying coating loaded on the substrate;

[0009] The metal ion polyphenol drug-carrying coating contains a polyphenol polymer, on which the first metal ion, the second metal ion and the drug are combined;

[0010] The first metal ion is a strontium ion, the second metal ion is selected from at least one of a copper ion and a zinc ion, and the drug is at least one of a polypeptide and a protein.

[0011] In an optional embodiment, the total amount of the first metal ion and the second metal ion accounts for 1%-50% by weight in the metal ion polyphenol drug-loaded coating, and the drug accounts for 1%-30% by weight in the metal ion polyphenol drug-loaded coating;

[0012] Preferably, the molar ratio of the first metal ion to the second metal ion is (1-100):1; preferably (40-60):1.

[0013] In an optional embodiment, the polyphenol polymer is obtained by polymerizing plant polyphenols containing a polyhydroxyphenol chemical structure;

[0014] Preferably, the plant polyphenols are selected from at least one of proanthocyanidins, resveratrol, tannic acid, quercetin, epicatechin, epicatechin gallate, epigallocatechin, epigallocatechin gallate, dopamine, levodopa, dextrodopa, gallic acid and its derivatives, salvianolic acid, caffeic acid, oleanolic acid, seabuckthorn acid, rutin, fuccinol, benzoic acid, matrine, kaempferol, theaflavins, ellagic acid, ellagitannins and brown algae polyphenols.

[0015] In an optional embodiment, the substrate is selected from at least one of a metal material, an inorganic non-metal material and a polymer material;

[0016] Preferably, the metal material includes stainless steel, iron and its alloys, aluminum and its alloys, magnesium and its alloys, copper and its alloys, titanium and its alloys, zinc and its alloys, uranium and its alloys, and cobalt-based alloys;

[0017] Preferably, the inorganic non-metallic material includes ceramics, glass, titanium dioxide, titanium oxide, titanium nitride, silicon dioxide, silicon carbide, carbon materials, calcium phosphate, aluminosilicate, calcium aluminum bioglass, hydroxyapatite, calcium phosphate silicon nitride, diamond and diamond-like carbon;

[0018] Preferably, the polymer material includes polyester, polyethylene, polyurethane, polyvinyl alcohol, polyvinyl chloride, polypropylene, polycarbonate, carbon copolymer, polyglycolic acid, polymethyl methacrylate, polytetrafluoroethylene, polyoxymethylene, polyvinyl acetate, polystyrene polylactic acid, polylactic acid-glycolic acid copolymer, polyhydroxyalkanoate, polytrimethylene carbonate, polybutylene succinate, polyamide, polyacrylic acid and its derivatives, polyethylene glycol and its derivatives, polyvinyl alcohol, polycaprolactone and polyurethane, epoxy resin, silicone rubber and silicone gel.

[0019] In an optional embodiment, the polypeptide includes hirudin and its derivatives, prednisone, bivalirudin, Argentine snake toxin, rivaroxaban, apixaban, dabigatran, antimicrobial peptide LL-37, antimicrobial peptide hCAP-18, antimicrobial peptide C, antimicrobial peptide BLP-7, β-defensin, teriparatide, osteocalcin, octreotide, antidiuretic hormone, oxytocin, lantreotide, brain natriuretic peptide, pidotimod, thymosin, gamma globulin, immunoglobulin and vasoactive peptides;

[0020] And / or, the protein includes lactoferrin, soy protein, whey protein, osteocalcin, insulin, collagen, osteosulfonin, cathepsin S, lysozyme, glucose oxidase, pepsin, horseradish peroxidase, glucose oxidase, pepsin, horseradish peroxidase, hemoglobin, cytochrome C, immunoglobulin G, fibrinogen, trypsin, insulin, growth hormone, heparin, glucosamine, calcitonin and erythropoietin.

[0021] In a second aspect, the present invention provides a method for preparing a metal ion polyphenol drug-carrying coating material according to any one of the aforementioned embodiments, comprising: immersing a substrate in a mixed solution containing a polyphenol compound, a first metal ion and a second metal ion to react and form a metal ion polyphenol coating;

[0022] The substrate with the metal ion polyphenol coating is immersed in a drug solution for reaction.

[0023] In an optional embodiment, in the mixed solution, the molar ratio of the first metal ion to the polyphenol is (0.01-10):1, and the molar ratio of the second metal ion to the polyphenol is (0.01-0.20):1;

[0024] Preferably, when the second metal ion is a copper ion, the molar ratio of the copper ion to the polyphenol is controlled to be (0.01-0.10):1; when the second metal ion is a zinc ion, the molar ratio of the zinc ion to the polyphenol is controlled to be (0.01-0.20):1;

[0025] Preferably, in the mixed solution, the final concentration of polyphenol is 0.01 mg / mL-50 mg / mL, the final concentration of the first metal ion is 0.01 mg / mL-50 mg / mL; the final concentration of copper ions is 0 μg / mL-300 μg / mL, and the final concentration of zinc ions is 0 μg / mL-600 μg / mL.

[0026] In an optional embodiment, the pH value of the mixed solution is 5-10, the reaction temperature is 10°C-75°C, and the reaction time is 0.1h-24h;

[0027] Preferably, the pH value of the mixed solution is 8-9, the reaction temperature is 15°C-37°C, and the reaction time is 0.5h-20h; more preferably, the reaction temperature is 25°C-37°C, and the reaction time is 12h-18h; more preferably, the preparation method further comprises: after the reaction is completed, taking out the material for washing and drying;

[0028] Preferably, the preparation process of the mixed solution comprises: mixing polyphenol, strontium salt, salt containing a second metal ion and a solvent having a pH value that meets the requirements, wherein the salt containing the second metal ion is at least one of a copper salt and a zinc salt;

[0029] More preferably, the strontium salt is selected from at least one of strontium chloride, strontium bromide, strontium iodide, strontium acetate, strontium nitrate and strontium nitrite; more preferably, the copper salt is selected from at least one of copper sulfate, copper chloride, cuprous chloride, copper acetate, copper acetate, copper fluoride, copper bromide, cuprous bromide, copper iodide, cuprous iodide, copper citrate, copper tartrate, copper propionate, copper nitrate and ammonia copper ion; more preferably, the zinc salt is selected from at least one of zinc sulfate, zinc chloride, zinc nitrate, zinc acetate and zinc fluoride;

[0030] More preferably, the solvent is a buffer solution with a pH value of 5-10; more preferably, the buffer solution is selected from at least one of bicarbonate buffer, PBS buffer, acetic acid / sodium acetate buffer and sodium hydroxide solution; further preferably, the buffer solution is sodium hydroxide solution, and the concentration of the sodium hydroxide solution is 0.001 mol / L-0.01 mol / L.

[0031] In an optional embodiment, the substrate having the metal ion polyphenol coating is immersed in a drug solution and reacted at 10° C. to 50° C. for 0.5 h to 48 h;

[0032] Preferably, the reaction temperature of the drug solution is 25°C-37°C, and the reaction time is 12h-24h;

[0033] Preferably, the concentration of the drug in the drug solution is 0.01 mg / mL-100 mg / mL, more preferably 0.5 mg / mL-20 mg / mL;

[0034] Preferably, the drug solution is obtained by mixing the drug and an alkaline mixed solution;

[0035] More preferably, the alkaline buffer solution includes at least one of a carbamate buffer, a bicarbonate buffer, a PBS buffer, a Tris-HCl buffer, an ethanolamine buffer, a sodium hydroxide solution and a potassium hydroxide solution; further preferably, the alkaline buffer solution is a PBS buffer, and the concentration of the alkaline buffer solution is 0.0001 mol / L-30 mol / L.

[0036] In a third aspect, the present invention provides a use of the metal ion polyphenol drug-loaded coating material of any one of the aforementioned embodiments or the metal ion polyphenol drug-loaded coating material prepared by any one of the preparation methods of the aforementioned embodiments in the preparation of implantable medical devices;

[0037] Preferably, the implanted medical device is selected from at least one of a vascular stent, a central venous catheter, a wound dressing and an artificial joint.

[0038] The present invention has the following beneficial effects: by combining the first metal ion, the second metal ion and the drug on the polyphenol polymer, a multifunctional drug-carrying coating is prepared. 2+ , Cu 2+ / Zn 2+ The formed metal phenolamine network may not only enhance the physiological effects of plant polyphenols and metal ions themselves, but also exert a synergistic effect to produce stronger antioxidant, anti-inflammatory, antibacterial and other biological activities. By introducing copper ions, long-term, controllable and stable catalytic release of NO can also be achieved, giving it more, stronger and more excellent performance. In addition, based on the physical adsorption between polyphenols and polypeptides or proteins, in-situ drug loading is achieved, and the polypeptide or protein has a long-lasting and stable sustained release performance. The metal ion polyphenol drug-loaded coating material provided by the present invention can simultaneously improve the ability of the coating to promote endothelial cell adhesion and proliferation, inhibit the adhesion and proliferation of smooth muscle cells, and can achieve a stable sustained release performance of biological functional macromolecules, and has a very good application prospect.

[0039] In addition, the metal ion polyphenol drug-loaded coating provided by the present invention has a broad spectrum, is independent of the substrate material, and has broad application prospects in the field of biomaterial technology. The functional coating has chemical stability, a simple production process, low cost, and is convenient for large-scale production and application. BRIEF DESCRIPTION OF THE DRAWINGS

[0040] In order to more clearly illustrate the technical solutions of the embodiments of the present invention, the drawings required for use in the embodiments are briefly introduced below. It should be understood that the following drawings only show certain embodiments of the present invention and therefore should not be regarded as limiting the scope. For ordinary technicians in this field, other related drawings can be obtained based on these drawings without creative work.

[0041] Figure 1 is the SEM image of Experimental Example 1 on a 316L-SS bracket;

[0042] Figure 2 is the SEM image of Experimental Example 2 on the cobalt-chromium alloy bracket;

[0043] Figure 3 These are scanning electron microscope photos of the anti-platelet adhesion and activation test results of Comparative Example 1 and Example 1;

[0044] Figure 4 These are fluorescent photos of endothelial cell adhesion and proliferation experiments in Comparative Example 2 and Example 3;

[0045] Figure 5 Fluorescence photos of smooth muscle cell adhesion and proliferation experiments in Comparative Example 5 and Example 4;

[0046] Figure 6 The drug release curves of slowly releasing bivalirudin in Example 3 and Comparative Example 4 are as follows;

[0047] Figure 7 Fluorescence photos of endothelial cell adhesion and proliferation experiments in Example 4 and Comparative Example 3;

[0048] Figure 8 Fluorescence photos of endothelial cell adhesion and proliferation experiments in Example 1 and Experimental Example 12;

[0049] Fig. 9 1 is the drug release curve of bivalirudin and octreotide in Example 1 and Experimental Example 15;

[0050] Fig.10 The thickness of the coating on the 316L-SS bracket of Example 1 and the thickness of the coating on the cobalt-chromium alloy bracket of Example 2. DETAILED DESCRIPTION

[0051] In order to make the purpose, technical scheme and advantages of the embodiments of the present invention clearer, the technical scheme in the embodiments of the present invention will be described clearly and completely below. If the specific conditions are not specified in the embodiments, they are carried out according to conventional conditions or conditions recommended by the manufacturer. If the manufacturer of the reagents or instruments used is not specified, they are all conventional products that can be purchased commercially.

[0052] The embodiment of the present invention provides a method for preparing a metal ion polyphenol drug-loaded coating material, comprising the following steps:

[0053] S1. Preparation of mixed solution

[0054] A mixed solution containing a polyphenol compound, a first metal ion and a second metal ion is prepared for later use.

[0055] In actual operation, the preparation process of the mixed solution includes: evenly mixing polyphenols, strontium salts, salts containing second metal ions and solvents with pH values ​​that meet the requirements, wherein the salts containing second metal ions are at least one of copper salts and zinc salts, and can be at least one or more of copper salts and zinc salts.

[0056] The polyphenols may be plant polyphenols containing a polyhydroxyphenol chemical structure, and the specific types are not limited.

[0057] In some embodiments, the plant polyphenols are selected from proanthocyanidins, resveratrol, tannic acid, quercetin, epicatechin, epicatechin gallate, epigallocatechin, epigallocatechin gallate, dopamine, levodopa, dextrodopa, gallic acid and its derivatives, salvianolic acid, caffeic acid, oleanolic acid, seabuckthorn acid, rutin, fucanol, benzoic acid, matrine, kaempferol, theaflavins, ellagic acid, ellagitannins and brown algae polyphenols. The plant polyphenols can be any one or more of the above. The above plant polyphenols can better combine with metal ions and drugs, and a multifunctional coating can be prepared.

[0058] In some embodiments, the strontium salt is selected from at least one of strontium chloride (SrCl2), strontium bromide (SrBr2), strontium iodide (SrI2), strontium acetate (Sr(CH3COO)2), strontium nitrate (Sr(NO3)2) and strontium nitrite (Sr(NO2)2), and the strontium salt can be any one or more of the above.

[0059] In some embodiments, the copper salt is selected from copper sulfate (CuSO4), copper chloride (CuCl2), cuprous chloride (CuCl), copper acetate (Cu(CH3COO)2), copper acetate (Cu(C2H3O2)2), copper fluoride (CuF2), copper bromide (CuBr), cuprous bromide (CuBr2), copper iodide (CuI), cuprous iodide (CuI2), copper citrate (C6H6CuO7), copper tartrate (C4H4CuO6·3H2O), copper propionate (Cu(CO2CH3CH2)2), copper nitrate (Cu(NO3)2) and ammonia copper ion ([Cu(NH3)4] 2+ ), and the copper salt can be any one or more of the above.

[0060] In some embodiments, the zinc salt is selected from at least one of zinc sulfate, zinc chloride, zinc nitrate, zinc acetate and zinc fluoride, and the zinc salt can be any one or more of the above.

[0061] In some embodiments, the solvent is a buffer solution with a pH value of 5-10, so that the pH value of the mixed solution is approximately 5-10. In a preferred embodiment, the pH value of the mixed solution is pH 8-9, and polyphenols can be better deposited within this pH range. Specifically, the pH value of the mixed solution can be 5, 6, 7, 8, 9, 10, etc.

[0062] Furthermore, the buffer solution is selected from at least one of bicarbonate buffer, PBS buffer, acetic acid / sodium acetate buffer and sodium hydroxide solution. The buffer solution can be any one of the above, and the pH value of the mixed solution can meet the requirements.

[0063] In a preferred embodiment, the buffer solution is a sodium hydroxide solution, and the concentration of the sodium hydroxide solution is 0.001mol / L-0.01mol / L, such as 0.001mol / L, 0.003mol / L, 0.005mol / L, 0.008mol / L, 0.010mol / L, etc.

[0064] Furthermore, in the mixed solution, the molar ratio of the first metal ion to the polyphenol is (0.01-10):1, and the molar ratio of the second metal ion to the polyphenol is (0.01-0.20):1. Preferably, when the second metal ion is a copper ion, the molar ratio of the copper ion to the polyphenol is controlled to be (0.01-0.10):1; when the second metal ion is a zinc ion, the molar ratio of the zinc ion to the polyphenol is controlled to be (0.01-0.20):1. By regulating the molar ratio of the first metal ion, the second metal ion and the polyphenol to meet the above range, the ability of the coating to promote the adhesion and proliferation of endothelial cells and inhibit the adhesion and proliferation of smooth muscle cells can be improved at the same time.

[0065] Specifically, the molar ratio of the first metal ion to the polyphenol can be 0.01:1, 0.03:1, 0.05:1, 0.08:1, 0.10:1, 0.30:1, 0.50:1, 0.80:1, 1.00:1, 2.00:1, 3.00:1, 4.00:1, 5.00:1, 6.00:1, 7.00:1, 8.00:1, 9.00:1, 10.00:1, etc.; the molar ratio of the second metal ion to the polyphenol can be 0.01:1, 0.03:1, 0.05:1, 0.08:1, 0.10:1, 0.15:1, 0.20:1, etc.

[0066] By adjusting the amount of solvent, the final concentration of polyphenol in the mixed solution is 0.01 mg / mL-50 mg / mL, the final concentration of the first metal ion is 0.01 mg / mL-50 mg / mL; the final concentration of copper ion is 0 μg / mL-300 μg / mL, the final concentration of zinc ion is 0 μg / mL-600 μg / mL, and the final concentration of copper ion and zinc ion is 0 at different times. By controlling the above preferred molar ratio and concentration scheme, the effect of polyphenol and Sr can be better exerted. 2+ and Cu 2+ / Zn 2+ The specific properties of the polyphenols can form an optimal metal ion coating.

[0067] Specifically, in the mixed solution, the final concentration of polyphenols can be 0.01 mg / mL, 0.05 mg / mL, 0.10 mg / mL, 0.50 mg / mL, 1.00 mg / mL, 5.00 mg / mL, 10.00 mg / mL, 20.00 mg / mL, 30.00 mg / mL, 40.00 mg / mL, 50.00 mg / mL, etc.; the final concentration of the first metal ion can be 0.01 mg / mL, 0.05 mg / mL, 0.10 mg / mL, 0.50 mg / mL, 1.00 mg / mL, 5.00 mg / mL, 10.00 mg / mL, 20.00 mg / mL, 30.00 mg / mL, 40.00 mg / mL, 50.00 mg / mL, etc. mL, 40.00 mg / mL, 50.00 mg / mL, etc.; the final concentration of copper ions can be 0 μg / mL, 10 μg / mL, 50 μg / mL, 100 μg / mL, 150 μg / mL, 200 μg / mL, 250 μg / mL, 300 μg / mL, etc.; the final concentration of zinc ions can be 0 μg / mL, 10 μg / mL, 50 μg / mL, 100 μg / mL, 150 μg / mL, 200 μg / mL, 250 μg / mL, 300 μg / mL, 350 μg / mL, 400 μg / mL, 450 μg / mL, 500 μg / mL, 550 μg / mL, 600 μg / mL, etc.

[0068] S2. Preparation of metal ion polyphenol coating

[0069] The substrate is immersed in the mixed solution obtained in S1 to react, and in-situ chemical crosslinking is achieved through the coordination between polyphenols and metal ions, cation II and other interactions to obtain a metal ion polyphenol coating.

[0070] In some embodiments, the reaction temperature is 10°C-75°C, and the reaction time is 0.1h-24h; preferably, the reaction temperature is 15°C-37°C, and the reaction time is 0.5h-20h; more preferably, the reaction temperature is 25°C-37°C, and the reaction time is 12h-18h. By further optimizing the reaction temperature and time, the polyphenols and metal ions are fully reacted, in-situ chemical crosslinking is achieved, and the utilization rate of the raw materials is improved.

[0071] Specifically, the reaction temperature can be 10°C, 15°C, 20°C, 25°C, 37°C, 50°C, 75°C, etc.; the reaction time can be 0.1h, 0.5h, 1.0h, 5.0h, 10.0h, 15.0h, 20.0h, 24.0h, etc.

[0072] In some embodiments, after the reaction in the mixed solution is completed, the material is taken out for cleaning and drying. The reactants not deposited on the surface can be effectively removed by cleaning, and distilled water can be used for cleaning 3 times, each time for 3 minutes. After cleaning, it is placed in an oven for drying to obtain a multifunctional metal ion polyphenol drug-loaded coating.

[0073] The type of substrate is not limited, and a suitable substrate can be selected according to the application. In some embodiments, the substrate is selected from at least one of a metal material, an inorganic non-metallic material, and a polymer material, and the substrate can be any one or more of the above.

[0074] In some embodiments, the metal material includes stainless steel, iron and its alloys, aluminum and its alloys, magnesium and its alloys, copper and its alloys, titanium and its alloys, zinc and its alloys, uranium and its alloys, and cobalt-based alloys, and the substrate can be any one or more of the above metal materials.

[0075] In some embodiments, the inorganic non-metallic materials include ceramics, glass, titanium dioxide, titanium oxide, titanium nitride, silicon dioxide, silicon carbide, carbon materials, calcium phosphate, aluminosilicate, calcium aluminum bioglass, hydroxyapatite, calcium phosphate silicon nitride, diamond and diamond-like carbon, and the substrate can be any one or more of the above inorganic non-metallic materials.

[0076] In some embodiments, the polymer material includes polyester (PET), polyethylene (PE), polyurethane (PU), polyvinyl alcohol (PVA), polyvinyl chloride (PVC), polypropylene (PP), polycarbonate (PC), carbon copolymer (COP), polyglycolic acid (PLA), polymethyl methacrylate (PMMA), polytetrafluoroethylene (PTFE), polyoxymethylene (POM), polyvinyl acetate (EVA), polystyrene polylactic acid, polytrimethylene carbonate, polystyrene (PS), polylactic acid (PLA), polylactic acid-glycolic acid copolymer (PLGA), polyhydroxyalkanoates (PHAs), polytrimethylene carbonate (PTMC), polybutylene succinate (PBT), polyamide (PA), polyacrylic acid (PAA) and its derivatives, polyethylene glycol (PEG) and its derivatives, polyvinyl alcohol (PVA), polycaprolactone (PCL) and polyurethane (PU), epoxy resin (EP), silicone rubber (SR) and silicone gel (SG), and the substrate can be any one or more of the above polymer materials.

[0077] The coating provided by the embodiment of the present invention has multiple biological functions and is suitable for the surfaces of different types of metals, inorganic non-metals or polymer materials. The preparation method of the coating is simple and easy to operate. A wide range of adjustable parameters can be used in the coating preparation process to meet the needs of different materials in medical scenarios. The raw materials used are common substances in life, which are easy to obtain, have good biocompatibility, and have a stable chemical structure. After the coating is formed, the physiological functions of each substance are not affected, and they work together to exert physiological effects.

[0078] S3. Drug loading

[0079] The substrate with the metal ion polyphenol coating is immersed in a drug solution for reaction, and the drug contained in the drug solution can be at least one of a polypeptide and a protein, and can be one or more. During the reaction, the weak interaction (such as hydrogen bonding, etc.) between the polyphenol and the polypeptide or protein realizes in-situ drug loading, and a multifunctional metal ion polyphenol drug-loaded coating is obtained.

[0080] In some embodiments, the polypeptides include hirudin and its derivatives, prednisone, bivalirudin, Argentine snake toxin, rivaroxaban, apixaban, dabigatran, antimicrobial peptide LL-37, antimicrobial peptide hCAP-18, antimicrobial peptide C, antimicrobial peptide BLP-7, β-defensin, teriparatide, osteocalcin, octreotide, antidiuretic hormone, oxytocin, lantreotide, brain natriuretic peptide, pidotimod, thymosin, gamma globulin, immunoglobulin and vasoactive peptides. The drug can be any one or more of the above polypeptides, all of which are suitable for drug loading using the preparation method provided in the embodiments of the present invention.

[0081] In some embodiments, the protein includes lactoferrin, soy protein, whey protein, osteocalcin, insulin, collagen, osteosulfonate, cathepsin S, lysozyme, glucose oxidase, pepsin, horseradish peroxidase, glucose oxidase, pepsin, horseradish peroxidase, hemoglobin, cytochrome C, immunoglobulin G, fibrinogen, trypsin, insulin, growth hormone, heparin, glucosamine, calcitonin and erythropoietin. The drug can be any one or more of the above proteins, all of which are suitable for drug loading using the preparation method provided by the embodiment of the present invention.

[0082] In some embodiments, the substrate with the metal ion polyphenol coating is immersed in a drug solution and reacted at 10°C-50°C for 0.5h-48h to introduce the drug on the basis of the metal ion polyphenol coating. In a preferred embodiment, the reaction temperature of the drug solution is 25°C-37°C, and the reaction time is 12h-24h. By further regulating the reaction temperature and time, the drug loading amount is more suitable to achieve the purpose of stable sustained release of the drug.

[0083] Specifically, the reaction temperature in the drug solution is 10°C, 20°C, 25°C, 30°C, 37°C, 40°C, 50°C, etc.; the reaction time can be 0.5h, 1.0h, 5.0h, 10.0h, 12.0h, 20.0h, 24.0h, 30.0h, 40.0h, 48.0h, etc.

[0084] In some embodiments, the concentration of the drug in the drug solution is 0.01mg / mL-100mg / mL, preferably 0.5mg / mL-20mg / mL, and the concentration of the drug in the drug solution is optimized, and the loading amount of the drug is further controlled to achieve stable sustained release of the drug. Specifically, the concentration of the drug in the drug solution can be 0.01mg / mL, 0.10mg / mL, 0.50mg / mL, 1.00mg / mL, 10.00mg / mL, 20.00mg / mL, 30.00mg / mL, 40.00mg / mL, 50.00mg / mL, 60.00mg / mL, 70.00mg / mL, 80.00mg / mL, 90.00mg / mL, 100.00mg / mL, etc.

[0085] In some embodiments, the drug solution is obtained by mixing the drug and an alkaline mixed solution to further control the pH value during the drug loading process and promote drug loading.

[0086] Further, the alkaline buffer solution includes at least one of carbamate buffer, bicarbonate buffer, PBS buffer, Tris-HCl buffer, ethanolamine buffer, sodium hydroxide solution and potassium hydroxide solution, and the alkaline buffer solution can be any one or more of the above buffers. Preferably, the alkaline buffer solution is PBS buffer, and the PBS buffer raw material is easy to obtain, and the pH value is more suitable for loading drugs. The concentration of the alkaline buffer solution is 0.0001mol / L-30mol / L, such as 0.0001mol / L, 0.0005mol / L, 0.0010mol / L, 0.0050mol / L, 0.0100mol / L, 0.0500mol / L, 0.1000mol / L, 0.5000mol / L, 1.0000mol / L, 5.0000mol / L, 10.0000mol / L, 20.0000mol / L, 30.0000mol / L, etc.

[0087] The embodiment of the present invention also provides a metal ion polyphenol drug-loaded coating material, comprising a substrate and a metal ion polyphenol drug-loaded coating loaded on the substrate, wherein the metal ion polyphenol drug-loaded coating contains a polyphenol polymer, and the polyphenol polymer is combined with a first metal ion, a second metal ion and a drug.

[0088] Furthermore, the first metal ion is a strontium ion, and the second metal ion is selected from at least one of a copper ion and a zinc ion, and the second metal ion can be any one or two of the above; the drug is at least one of a polypeptide and a protein, and the drug can be at least one polypeptide, at least one protein, or a mixture of polypeptides and proteins.

[0089] It should be noted that strontium ions (Sr 2+ ) has a variety of physiological effects in the human body, such as promoting osteogenesis, anti-inflammation, anti-oxidation, and participating in angiogenesis. 2+ ) and zinc ions (Z n2+ ) is an essential trace element for the human body, and has significant anti-inflammatory, antibacterial, and active oxygen free radical scavenging functions. 2+ / Zn 2+ It also has a powerful oxidation catalytic function, such as catalyzing S-nitrosothiol in the human body to release NO, thereby playing a cardiovascular and cerebrovascular protective role. 2 + , Cu 2+ / Zn 2+ The constructed metal phenolamine coating has broader and more powerful biological activity.

[0090] In some embodiments, the molar ratio of the first metal ion to the second metal ion is (1-100):1, such as 1:1, 1:5, 1:10, 1:20, 1:30, 1:40, 1:50, 1:60, 1:70, 1:80, 1:90, 1:100, etc.; preferably (40-60):1, the molar ratio of the first metal ion to the second metal ion is preferably within the above range, which can further enhance the ability of the coating to promote endothelial cell adhesion and proliferation, and at the same time enhance the ability of the coating to inhibit smooth muscle cell adhesion and proliferation. The total amount of the first metal ion and the second metal ion in the metal ion polyphenol drug-loaded coating accounts for 1%-50% by weight (such as 1%, 10%, 20%, 30%, 40%, 50%, etc.), and the drug accounts for 1%-30% by weight in the metal ion polyphenol drug-loaded coating (such as 1%, 5%, 10%, 20%, 30%, etc.).

[0091] The application of the metal ion polyphenol drug-loaded coating material provided in the embodiment of the present invention in the preparation of implantable medical devices can be used to prepare the surface layer of implantable medical devices, which has the effects of protecting the cardiovascular system, promoting bone regeneration, anti-inflammatory, antibacterial, and anti-thrombotic. It can also catalyze the release of NO, giving it more excellent performance.

[0092] Furthermore, the implanted medical device is selected from at least one of a vascular stent, a central venous catheter, a wound dressing and an artificial joint, and the implanted medical device may be any one or more of the above.

[0093] The features and performance of the present invention are further described in detail below in conjunction with the embodiments.

[0094] Example 1

[0095] This embodiment provides a method for preparing a metal ion polyphenol drug-carrying coating material, comprising the following steps:

[0096] (1) Wash 316L SS thoroughly with distilled water, then ultrasonically clean it with anhydrous ethanol three times, 5 minutes each time, and then ultrasonically clean it with acetone three times, and dry it in an oven for later use.

[0097] (2) Proanthocyanidin (purchased from damas-beta, model number p1523063) and SrCl2 were mixed in distilled water at a molar ratio of 1:2, and ultrasonicated for 10 minutes to fully dissolve the proanthocyanidin to obtain a mixed solution A with a pH of 8. Proanthocyanidin and CuCl2 were then mixed in distilled water at a molar ratio of 1:0.03 to obtain a mixed solution B with a pH of 8. Then, solution A and solution B were mixed to obtain a final concentration of proanthocyanidin of 2.5 mg / mL, a final concentration of SrCl2 of 2.5 mg / mL, and a final concentration of CuCl2 of 25 ug / mL. (After conversion, the molar ratio of proanthocyanidin, strontium ion, and copper ion is 5.337:15.76:0.1859)

[0098] (3) Immerse the 316L SS to be used in the above mixed solution and gently mix it. Then place it in a constant temperature box at 25°C for 14 hours to perform the first reaction deposition.

[0099] (4) After the reaction is completed, the material is taken out and gently rinsed with distilled water three times. The surface water is absorbed from the side with filter paper and then dried in an oven to obtain a metal ion polyphenol coating sample with multifunctionality.

[0100] (5) Dissolve bivalirudin in PBS buffer solution and shake evenly to make the final concentration of bivalirudin 1 mg / mL.

[0101] (6) Immersing the metal ion polyphenol coating sample obtained in step (4) into the bivalirudin solution system, and then placing it in a 25° C. constant temperature box for 12 hours for a second reaction to obtain a multifunctional metal ion polyphenol drug-loaded coating.

[0102] Example 2

[0103] This embodiment is basically the same as the embodiment 1, except that the substrate is replaced with a cobalt-chromium alloy.

[0104] Example 3

[0105] This example is basically the same as Example 1, except that the polyphenols are replaced with an equimolar amount of epicatechin gallate ECG (purchased from Aladdin, model number G329710), i.e., the molar amount of polyphenols in the total mixed solution obtained in step (2) remains unchanged.

[0106] Example 4

[0107] This embodiment provides a method for preparing a metal ion polyphenol drug-carrying coating material, comprising the following steps:

[0108] (1) The silicone rubber substrate was thoroughly cleaned with distilled water, and then ultrasonically cleaned with anhydrous ethanol for three times, each time for 5 minutes, and then dried in an oven for later use.

[0109] (2) Resveratrol (purchased from Aladdin, model number R408711) and SrCl2 were mixed in distilled water at a molar ratio of 1:1, and ultrasonicated for 10 minutes to fully dissolve resveratrol to obtain a mixed solution A with a pH of 8.5. Resveratrol and ZnCl2 were then mixed in distilled water at a molar ratio of 1:0.05 to obtain a mixed solution B with a pH of 9. Then, solution A and solution B were mixed to obtain a final concentration of resveratrol of 3 mg / mL, a final concentration of SrCl2 of 3 mg / mL, and a final concentration of ZnCl2 of 50 ug / mL. (After conversion, the molar ratio of resveratrol, strontium ion, and zinc ion is 13.144:18.913:0.3668)

[0110] (3) Immerse the silicone rubber substrate to be used in the above mixed solution, gently mix it, and then place it in a constant temperature box at 37°C for 12 hours to perform reaction deposition.

[0111] (4) After the reaction is completed, the silicone rubber substrate is taken out and gently rinsed with distilled water for three times. The surface water is absorbed from the side with filter paper and then dried in an oven to obtain a metal ion polyphenol coating sample with multifunctionality.

[0112] (5) Dissolve antimicrobial peptide C in PBS buffer solution and shake evenly to make the final concentration of antimicrobial peptide C 3 mg / mL.

[0113] (6) Immersing the metal ion polyphenol coating sample obtained in step (4) into the antimicrobial peptide C solution system, and then placing it in a 25° C. incubator for 24 hours for a second reaction to obtain a multifunctional metal ion polyphenol drug-loaded coating.

[0114] Example 5

[0115] This example is basically the same as Example 4, except that the polyphenols are replaced with an equal molar amount of epicatechin (purchased from Aladdin, model number E107318), i.e., the molar amount of polyphenols in the total mixed solution obtained in step (2) remains unchanged.

[0116] Example 6

[0117] This example is basically the same as Example 4, except that the polyphenols are replaced with an equal molar amount of ellagic acid (purchased from Aladdin, model number E102710), i.e., the molar amount of polyphenols in the total mixed solution obtained in step (2) remains unchanged.

[0118] Example 7

[0119] This embodiment provides a method for preparing a metal ion polyphenol drug-carrying coating material, comprising the following steps:

[0120] (1) The titanium dioxide sheet was thoroughly cleaned with distilled water, then ultrasonically cleaned with anhydrous ethanol for three times, each time for 5 minutes, then ultrasonically cleaned with acetone for three times, and dried in an oven for later use.

[0121] (2) Quercetin (purchased from Aladdin, model number Q111274) was mixed with SrCl2 in a molar ratio of 1:1 in distilled water, and ultrasonicated for 10 minutes to fully dissolve the gallic acid to obtain a mixed solution A with a pH of 8.5. Quercetin was then mixed with CuCl2 in a molar ratio of 1:0.03 in distilled water to obtain a mixed solution B with a pH of 8.5. Then, solution A and solution B were mixed to obtain a final concentration of quercetin of 3 mg / mL, a final concentration of SrCl2 of 3 mg / mL, and a final concentration of CuCl2 of 25 ug / mL. (After conversion, the molar ratio of quercetin, strontium ion, and copper ion was 53.4:101.8:1)

[0122] (3) Immerse the titanium dioxide sheet to be used in the above mixed solution, gently mix it, and then place it in a constant temperature box at 25°C for 14 hours to perform reaction deposition.

[0123] (4) After the reaction is completed, the titanium dioxide sheet is taken out and gently rinsed with distilled water for three times. The water on the surface is absorbed from the side with filter paper and then dried in an oven to obtain a metal ion polyphenol coating sample with multifunctionality.

[0124] (5) Dissolve octreotide in PBS buffer solution and shake evenly to make the final concentration of octreotide 10 mg / mL.

[0125] (6) Immersing the metal ion polyphenol coating sample obtained in step (4) into the octreotide solution system, and then placing it in a 37° C. incubator for 36 hours to perform a second reaction, thereby obtaining a multifunctional metal ion polyphenol drug-loaded coating.

[0126] Example 8

[0127] This embodiment is basically the same as embodiment 7, except that the pH value of the mixed solution obtained in step (2) is 10, the reaction temperature is 25° C., and the first reaction time is 24 h.

[0128] Example 9

[0129] This example is basically the same as Example 7, except that the final concentration of CuCl2 is 100 ug / mL (after conversion, the molar ratio of quercetin, strontium ion, and copper ion is 13.35:25.43:1).

[0130] Example 10

[0131] This embodiment is basically the same as embodiment 7, except that the polypeptide is replaced by insulin.

[0132] Embodiment 11

[0133] This embodiment provides a method for preparing a metal ion polyphenol drug-carrying coating material, comprising the following steps:

[0134] (1) The glass sheet was thoroughly cleaned with distilled water, then ultrasonically cleaned with anhydrous ethanol three times, each time for 5 minutes, then ultrasonically cleaned with acetone three times, and dried in an oven for later use.

[0135] (2) Caffeic acid (purchased from Aladdin, model number C423391) and SrCl2 were mixed in distilled water at a molar ratio of 1:2, and ultrasonicated for 10 min to fully dissolve the caffeic acid to obtain a mixed solution A with a pH of 9. Caffeic acid and ZnCl2 were then mixed in distilled water at a molar ratio of 1:0.03 to obtain a mixed solution B with a pH of 9. Then, solution A and solution B were mixed to obtain a final concentration of caffeic acid of 10 mg / mL, a final concentration of SrCl2 of 10 mg / mL, and a final concentration of ZnCl2 of 25 ug / mL.

[0136] (3) Immerse the glass sheet to be used in the above mixed solution, gently mix it, and then place it in a constant temperature box at 25°C for 20 hours to perform reaction deposition.

[0137] (4) After the reaction is completed, the glass sheet is taken out and gently rinsed with distilled water for three times. The surface water is absorbed from the side with filter paper and then dried in an oven to obtain a metal ion polyphenol coating sample with multifunctionality.

[0138] (5) Dissolve calcitonin in PBS buffer solution and shake evenly to make the final concentration of calcitonin 20 mg / mL.

[0139] (6) Immersing the metal ion polyphenol coating sample obtained in step (4) into the calcitonin solution system, and then placing it in a 37° C. incubator for 48 hours to perform a second reaction, thereby obtaining a multifunctional metal ion polyphenol drug-loaded coating.

[0140] Example 12

[0141] The only difference between this embodiment and embodiment 1 is that the content of each component in the total mixed solution prepared in step (2) is changed so that the molar ratio of proanthocyanidins, strontium ions and copper ions is 70:150:1.

[0142] Example 13

[0143] The only difference between this embodiment and embodiment 1 is that the content of each component in the total mixed solution prepared in step (2) is changed so that the molar ratio of proanthocyanidins, strontium ions and copper ions is 50:90:1.

[0144] Embodiment 14

[0145] The only difference between this embodiment and embodiment 1 is that the copper ions in step (2) are replaced by an equimolar amount of zinc ions.

[0146] Embodiment 15

[0147] The only difference between this embodiment and embodiment 1 is that in step (5), bivalirudin is replaced by octreotide of equal concentration.

[0148] Example 16

[0149] The only difference between this example and Example 1 is that in step (5), bivalirudin is replaced by teriparatide of equal concentration.

[0150] Comparative Example 1

[0151] The difference between this comparative example and Example 1 is that no CuCl2 is added, so that the molar amount of strontium ions added to the total mixed solution obtained in step (2) is equal to the total amount of copper ions and strontium ions added in Example 1.

[0152] Comparative Example 2

[0153] The only difference between this comparative example and Example 3 is that SrCl2 is not added, so that the molar amount of copper ions added to the total mixed solution obtained in step (2) is equal to the total amount of copper ions and strontium ions added in Example 1.

[0154] Comparative Example 3

[0155] The difference between this comparative example and Example 4 is that no second reaction is carried out, that is, only steps (1) to (4) are carried out.

[0156] Silicone rubber catheter was used as the substrate, and the final concentration of resveratrol, SrCl2 and ZnCl2 was controlled to be 3 mg / mL, 3 mg / mL and 50 ug / mL, respectively. The tube was reacted at 37°C for 12 hours, washed with distilled water three times, dried in an oven, and placed in a dry environment at 37°C for later use.

[0157] Comparative Example 4

[0158] The only difference between this comparative example and Example 3 is that the pH of the distilled water is adjusted to 10 and the temperature of the second reaction is adjusted to 50°C.

[0159] The substrate was 316L SS, and the final concentration of ECG, SrCl2, and CuCl2 was controlled to be 2.5 mg / mL, 2.5 mg / mL, and 50 ug / mL. The reaction was carried out at 37°C for 12 hours, and then washed with distilled water three times, dried in an oven, and then placed in a 1 mg / mL bivalirudin solution system, and placed in a 50°C thermostat for 12 hours for the second reaction. After being taken out, washed, and dried, it was placed in a 37°C dry environment for use.

[0160] Comparative Example 5

[0161] The only difference between this comparative example and Example 4 is that SrCl2 and CuCl2 are not added in step (2).

[0162] Test Example 1

[0163] The microscopic morphology of the surface coating of the medical 316L SS stent prepared in Example 1 is as follows: Figure 1 As shown, it can be seen that the coating maintains good adhesion on the surface of the stent and is deposited evenly without obvious cracking, proving that the coating can fully adapt to the deformation of the stent during expansion and compression.

[0164] Test Example 2

[0165] The microscopic morphology of the surface coating of the medical cobalt-chromium alloy vascular stent prepared in Example 2 was tested. The results are as follows: Figure 2 As shown, it can be seen that the coating maintains good adhesion on the surface of the stent and is deposited evenly without obvious cracking, proving that the coating can fully adapt to the deformation of the stent during expansion and compression.

[0166] Test Example 3

[0167] Platelet adhesion and activation experiments were performed using the materials obtained in Example 1 and Comparative Example 1. The results are as follows: Figure 3 shown.

[0168] Experimental methods:

[0169] (1) The materials prepared in Example 1 and Comparative Example 1 were compared using a static platelet adhesion experiment. First, whole blood from healthy New Zealand rabbits was collected using a vacuum negative pressure tube containing sodium citrate anticoagulant. Platelet-rich plasma (PRP) was collected by centrifugation at 1500 rpm for 15 min.

[0170] (2) Add 200 μL of fresh PRP to the surfaces of the two coatings and incubate at 37°C for 30 min. Wash the non-adherent platelets with saline, fix them in 2.5% glutaraldehyde solution for 12 h, dehydrate them with ethanol, and observe the morphology and number of platelets using a scanning electron microscope.

[0171] from Figure 3 It can be seen that the number of platelets adhered and the degree of activation on the surface of Example 1 are significantly less than those of Comparative Example 1, showing excellent anti-platelet adhesion and activation functions, indicating that Example 1 has better blood compatibility.

[0172] Test Example 4

[0173] The materials obtained in Test Example 3 and Comparative Example 2 were subjected to endothelial cell adhesion and proliferation experiments. The fluorescence photos are shown in FIG. Figure 4 shown.

[0174] Test method: Endothelial cells were planted on the surface of the materials prepared in Example 3 and Comparative Example 2, and photographed under an inverted fluorescence microscope after being cultured for 24 hours and 72 hours, respectively.

[0175] from Figure 4 It can be seen that the number of endothelial cells adhered to the surface of Example 3 is significantly higher than that of Comparative Example 2, and the proliferation is also more excellent, indicating that Example 3 has a more significant ability to promote endothelial cell adhesion and proliferation.

[0176] It can be seen that copper ions promote the adhesion and proliferation of endothelial cells, while strontium ions and copper ions have a synergistic effect, which can enhance the adhesion and proliferation of endothelial cells.

[0177] Test Example 5

[0178] The materials obtained in Test Example 4 and Comparative Example 5 were subjected to smooth muscle cell adhesion and proliferation experiments. The fluorescence photos are shown in FIG. Figure 5 shown.

[0179] Test method: Smooth muscle cells were planted on the surface of the materials prepared in Example 4 and Comparative Example 5, and photographed under an inverted fluorescence microscope after culturing for 24 hours and 72 hours, respectively.

[0180] from Figure 5It can be seen that the number of smooth muscle cells adhered to the surface of Example 4 is significantly lower than that of Comparative Example 5, and the proliferation is also inhibited, indicating that Example 4 has a more significant ability to inhibit the adhesion and proliferation of smooth muscle cells.

[0181] Test Example 6

[0182] The release amount of BVLD corresponding to Example 3 and Comparative Example 4 was detected by fluorescent labeling method according to the following method. The results are as follows: Figure 6 shown.

[0183] Test method:

[0184] (1) A molecule of fluorescein (named BVLD-Fluor) is pre-labeled on bivalirudin.

[0185] (2) According to the experimental steps given in Example 3 and Comparative Example 4, multifunctional metal ion polyphenol drug-loaded coatings for releasing bivalirudin were prepared respectively.

[0186] (3) The coating samples in Example 3 and Comparative Example 4 were placed in PBS buffer solution, and the extracts were collected at 1, 3, 7, 15, and 30 days for later use.

[0187] (4) Since the BVLD-Fluor released in the coating elution test absorbs light at a wavelength of 490 nm, the absorption intensity at this wavelength can be measured by a UV-vis spectrophotometer and the BVLD elution amount can be calculated based on the standard curve.

[0188] according to Figure 6 The results show that after 5 days of PBS immersion, the release of BVLD in the coating of Comparative Example 4 was observed to be balanced, and the cumulative release amount was 157.3 μg. In contrast, the coating in Example 3 needed 15 days of PBS immersion to reach the equilibrium state of release, and the cumulative release amount was 620 μg. This shows that the preparation of the coating designed to release bivalirudin in Example 3 is more successful.

[0189] Test Example 7

[0190] The materials obtained in Test Example 4 and Comparative Example 3 were subjected to endothelial cell adhesion and proliferation experiments. The fluorescence photos are shown in FIG. Figure 7 shown.

[0191] Test method: Endothelial cells were planted on the surface of the materials prepared in Example 4 and Comparative Example 3, and photographed under an inverted fluorescence microscope after being cultured for 24 hours and 72 hours, respectively.

[0192] from Figure 7 It can be seen that the number of endothelial cells adhered to the surface of Example 4 is significantly higher than that of Comparative Example 3, and the proliferation is also better, indicating that Example 4 has better cell biocompatibility.

[0193] Test Example 8

[0194] The materials obtained in Example 1 and Example 12 were subjected to endothelial cell adhesion and proliferation experiments. The fluorescence photos are shown in FIG. Figure 8 shown.

[0195] Test method: Endothelial cells were planted on the surface of the materials prepared in Example 1 and Example 12, and photographed under an inverted fluorescence microscope after being cultured for 24 hours and 72 hours, respectively.

[0196] from Figure 7 It can be seen that the number of endothelial cells adhered to the surface of Example 1 is significantly higher than that of Example 12, and the proliferation is also better, indicating that Example 1 has better cell biocompatibility.

[0197] Test Example 9

[0198] The release amounts of BVLD and Octreotide corresponding to Example 1 and Example 15 were detected by fluorescent labeling method as follows. The results are as follows: Figure 6 shown.

[0199] Test method:

[0200] (1) A molecule of fluorescein was pre-labeled on bivalirudin and octreotide (named Octreotide-Fluor and BVLD-Fluor).

[0201] (2) According to the experimental steps given in Example 1 and Example 15, multifunctional metal ion polyphenol drug-loaded coatings for releasing bivalirudin or octreotide were prepared respectively.

[0202] (3) The coating samples in Example 1 and Example 12 were placed in PBS buffer solution, and the extracts were collected at 1, 3, 7, 15, and 30 days for later use.

[0203] (4) Since the BVLD-Fluor and Octreotide-Fluor released in the coating elution test absorb light at a wavelength of 490 nm, the absorption intensity at this wavelength can be measured by a UV-vis spectrophotometer and the elution amount of bivalirudin or octreotide can be calculated based on the standard curve.

[0204] according to Fig. 9The results show that after the coating in Experimental Example 15 was soaked in PBS for 5 days, the release of BVLD was observed to be balanced, and the cumulative release amount was 125 μg. In contrast, the coating in Example 1 needed to be soaked in PBS for 15 days to reach the equilibrium state of release, and the cumulative release amount was 630 μg. This shows that the sustained release effect of the coating designed in Example 1 is better than that of the Bivalirudin.

[0205] Test Example 10

[0206] The thickness of the surface coating of the medical 316L SS vascular stent prepared in Example 1 and the surface coating of the medical cobalt-chromium alloy vascular stent prepared in Example 2 were tested. The results are as follows: Fig.10 As shown in the figure, it can be seen that the thickness of the coating on the cobalt-chromium alloy stent is significantly higher than that on the 316L SS vascular stent, indicating that the coating has better bonding with the cobalt-chromium alloy substrate.

[0207] By comparing the experimental results of the embodiments and comparative examples, it can be found that the various modified materials in the embodiments of the present application all have corresponding functional performances. According to the application scenario and scope of use, polyphenols, metal ions, polypeptides or proteins can be selected to construct a multifunctional metal phenolamine drug-carrying coating to achieve long-term, stable and controllable NO catalytic release and polypeptide or protein sustained release performance. By controlling the type of polyphenols, the concentration of polyphenols and metal ions, and the coating reaction time, an adjustable and controllable metal ion polyphenol drug-carrying coating for multi-scenario applications can be achieved.

[0208] In summary, the present invention discloses a metal ion polyphenol drug-loaded coating material, a preparation method and application thereof, and a multifunctional drug-loaded coating is prepared by combining a first metal ion, a second metal ion and a drug on a polyphenol polymer. The metal ion polyphenol coating is obtained by the coordination between polyphenols and metal ions, cation II and other interactions; based on the weak interaction forces between polyphenols and polypeptides or proteins such as hydrogen bonds, in-situ drug loading is achieved to obtain a multifunctional metal ion polyphenol drug-loaded coating. The coating prepared by the present invention has excellent long-term, stable, controllable NO catalytic release and polypeptide or protein sustained release performance, and has a broad spectrum, is independent of the substrate material, and has broad application prospects in the field of biomaterial technology. In addition, the functional coating has chemical stability, a simple production process, low cost, and is convenient for large-scale production and application.

[0209] The above are only preferred embodiments of the present invention and are not intended to limit the present invention. For those skilled in the art, the present invention may have various modifications and variations. Any modification, equivalent replacement, improvement, etc. made within the spirit and principle of the present invention shall be included in the protection scope of the present invention.

Claims

1. A metal ion polyphenol drug-carrying coating material, characterized in that: It comprises a substrate and a metal ion polyphenol drug-carrying coating loaded on the substrate; Wherein, the metal ion polyphenol drug-carrying coating contains a polyphenol polymer, and the polyphenol polymer is combined with a first metal ion, a second metal ion and a drug; The first metal ion is a strontium ion, the second metal ion is selected from at least one of a copper ion and a zinc ion, and the drug is at least one of a polypeptide and a protein.

2. The metal ion polyphenol drug-carrying coating material according to claim 1, characterized in that: The total amount of the first metal ion and the second metal ion in the metal ion polyphenol drug-carrying coating accounts for 1%-50% by weight, and the drug in the metal ion polyphenol drug-carrying coating accounts for 1%-30% by weight; Preferably, the molar ratio of the first metal ion to the second metal ion is (1-100):1; preferably (40-60):

1.

3. The metal ion polyphenol drug-carrying coating material according to claim 1 or 2, characterized in that: The polyphenol polymer is obtained by polymerizing plant polyphenols containing polyhydroxyphenol chemical structures; Preferably, the plant polyphenols are selected from at least one of proanthocyanidins, resveratrol, tannic acid, quercetin, epicatechin, epicatechin gallate, epigallocatechin, epigallocatechin gallate, dopamine, levodopa, dextrodopa, gallic acid and its derivatives, salvianolic acid, caffeic acid, oleanolic acid, seabuckthorn acid, rutin, fuccinol, benzoic acid, matrine, kaempferol, theaflavins, ellagic acid, ellagitannins and brown algae polyphenols.

4. The metal ion polyphenol drug-carrying coating material according to claim 1 or 2, characterized in that: The substrate is selected from at least one of a metal material, an inorganic non-metal material and a polymer material; Preferably, the metal material includes stainless steel, iron and its alloys, aluminum and its alloys, magnesium and its alloys, copper and its alloys, titanium and its alloys, zinc and its alloys, uranium and its alloys, and cobalt-based alloys; Preferably, the inorganic non-metallic material includes ceramics, glass, titanium dioxide, titanium oxide, titanium nitride, silicon dioxide, silicon carbide, carbon materials, calcium phosphate, aluminosilicate, calcium aluminum bioglass, hydroxyapatite, calcium phosphate silicon nitride, diamond and diamond-like carbon; Preferably, the polymer material includes polyester, polyethylene, polyurethane, polyvinyl alcohol, polyvinyl chloride, polypropylene, polycarbonate, carbon copolymer, polyglycolic acid, polymethyl methacrylate, polytetrafluoroethylene, polyoxymethylene, polyvinyl acetate, polystyrene polylactic acid, polylactic acid-glycolic acid copolymer, polyhydroxyalkanoate, polytrimethylene carbonate, polybutylene succinate, polyamide, polyacrylic acid and its derivatives, polyethylene glycol and its derivatives, polyvinyl alcohol, polycaprolactone and polyurethane, epoxy resin, silicone rubber and silicone gel.

5. The metal ion polyphenol drug-carrying coating material according to claim 1 or 2, characterized in that: The polypeptides include hirudin and its derivatives, prednisone, bivalirudin, Argentine snake toxin, rivaroxaban, apixaban, dabigatran, antimicrobial peptide LL-37, antimicrobial peptide hCAP-18, antimicrobial peptide C, antimicrobial peptide BLP-7, β-defensin, teriparatide, osteocalcin, octreotide, antidiuretic hormone, oxytocin, lantreotide, brain natriuretic peptide, pidotimod, thymosin, gamma globulin, immunoglobulin and vasoactive peptides; And / or, the protein includes lactoferrin, soy protein, whey protein, osteocalcin, insulin, collagen, osteosulfonin, cathepsin S, lysozyme, glucose oxidase, pepsin, horseradish peroxidase, glucose oxidase, pepsin, horseradish peroxidase, hemoglobin, cytochrome C, immunoglobulin G, fibrinogen, trypsin, insulin, growth hormone, heparin, glucosamine, calcitonin and erythropoietin.

6. A method for preparing the metal ion polyphenol drug-loaded coating material according to any one of claims 1 to 5, characterized in that: include: Immersing the substrate in a mixed solution containing a polyphenol compound, the first metal ion and the second metal ion to react and form a metal ion polyphenol coating; The substrate having the metal ion polyphenol coating is immersed in a drug solution for reaction.

7. The preparation method according to claim 6, characterized in that: In the mixed solution, the molar ratio of the first metal ion to the polyphenol is (0.01-10):1, and the molar ratio of the second metal ion to the polyphenol is (0.01-0.20):1; Preferably, when the second metal ion is a copper ion, the molar ratio of the copper ion to the polyphenol is controlled to be (0.01-0.10):1; when the second metal ion is a zinc ion, the molar ratio of the zinc ion to the polyphenol is controlled to be (0.01-0.20):1; Preferably, in the mixed solution, the final concentration of the polyphenol is 0.01 mg / mL-50 mg / mL, the final concentration of the first metal ion is 0.01 mg / mL-50 mg / mL; the final concentration of the copper ion is 0 μg / mL-300 μg / mL, and the final concentration of the zinc ion is 0 μg / mL-600 μg / mL.

8. The preparation method according to claim 7, characterized in that: The pH value of the mixed solution is 5-10, the reaction temperature is 10°C-75°C, and the reaction time is 0.1h-24h; Preferably, the pH value of the mixed solution is 8-9, the reaction temperature is 15°C-37°C, and the reaction time is 0.5h-20h; more preferably, the reaction temperature is 25°C-37°C, and the reaction time is 12h-18h; more preferably, the preparation method further comprises: after the reaction is completed, taking out the material for washing and drying; Preferably, the preparation process of the mixed solution comprises: mixing the polyphenol, strontium salt, salt containing the second metal ion and a solvent having a pH value that meets the requirements, wherein the salt containing the second metal ion is at least one of a copper salt and a zinc salt; More preferably, the strontium salt is selected from at least one of strontium chloride, strontium bromide, strontium iodide, strontium acetate, strontium nitrate and strontium nitrite; more preferably, the copper salt is selected from at least one of copper sulfate, copper chloride, cuprous chloride, copper acetate, copper acetate, copper fluoride, copper bromide, cuprous bromide, copper iodide, cuprous iodide, copper citrate, copper tartrate, copper propionate, copper nitrate and ammonia copper ion; more preferably, the zinc salt is selected from at least one of zinc sulfate, zinc chloride, zinc nitrate, zinc acetate and zinc fluoride; More preferably, the solvent is a buffer solution with a pH value of 5-10; more preferably, the buffer solution is selected from at least one of bicarbonate buffer, PBS buffer, acetic acid / sodium acetate buffer and sodium hydroxide solution; further preferably, the buffer solution is a sodium hydroxide solution, and the concentration of the sodium hydroxide solution is 0.001 mol / L-0.01 mol / L.

9. The preparation method according to claim 6, characterized in that: Immersing the substrate having the metal ion polyphenol coating in the drug solution, and reacting at 10° C. to 50° C. for 0.5 h to 48 h; Preferably, the reaction temperature of the drug solution is 25°C-37°C, and the reaction time is 12h-24h; Preferably, the concentration of the drug in the drug solution is 0.01 mg / mL-100 mg / mL, more preferably 0.5 mg / mL-20 mg / mL; Preferably, the drug solution is obtained by mixing the drug and an alkaline mixed solution; More preferably, the alkaline buffer solution includes at least one of a carbamate buffer, a bicarbonate buffer, a PBS buffer, a Tris-HCl buffer, an ethanolamine buffer, a sodium hydroxide solution and a potassium hydroxide solution; further preferably, the alkaline buffer solution is a PBS buffer, and the concentration of the alkaline buffer solution is 0.0001 mol / L-30 mol / L.

10. Use of the metal ion polyphenol drug-loaded coating material according to any one of claims 1 to 5 or the metal ion polyphenol drug-loaded coating material prepared by the preparation method according to any one of claims 6 to 9 in the preparation of implantable medical devices; Preferably, the implanted medical device is selected from at least one of a vascular stent, a central venous catheter, a wound dressing and an artificial joint.

Citation Information

Cited By

  • Hydrophilic and hydrophobic Janus membrane as well as preparation method and application thereof

    CN121130137A

  • Novel metal-polyphenol microspheres as well as preparation method and application thereof

    CN121265809A